Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer.

Puyang X, Furman C, Zheng GZ, Wu ZJ, Banka D, Aithal K, Agoulnik S, Bolduc DM, Buonamici S, Caleb B, Das S, Eckley S, Fekkes P, Hao MH, Hart A, Houtman R, Irwin S, Joshi JJ, Karr C, Kim A, Kumar N, Kumar P, Kuznetsov G, Lai WG, Larsen N, Mackenzie C, Martin LA, Melchers D, Moriarty A, Nguyen TV, Norris J, O'Shea M, Pancholi S, Prajapati S, Rajagopalan S, Reynolds DJ, Rimkunas V, Rioux N, Ribas R, Siu A, Sivakumar S, Subramanian V, Thomas M, Vaillancourt FH, Wang J, Wardell S, Wick MJ, Yao S, Yu L, Warmuth M, Smith PG, Zhu P, Korpal M.

Cancer Discov. 2018 Jul 10. doi: 10.1158/2159-8290.CD-17-1229. [Epub ahead of print]

PMID:
29991605
2.

Modulation of immunosurveillance by tumor-intrinsic genomic alterations.

Furman C, Zhu P, Korpal M.

Immunotherapy. 2017 Dec;9(16):1305-1307. doi: 10.2217/imt-2017-0132. No abstract available.

PMID:
29185394
3.

Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer.

Korpal M, Puyang X, Jeremy Wu Z, Seiler R, Furman C, Oo HZ, Seiler M, Irwin S, Subramanian V, Julie Joshi J, Wang CK, Rimkunas V, Tortora D, Yang H, Kumar N, Kuznetsov G, Matijevic M, Chow J, Kumar P, Zou J, Feala J, Corson L, Henry R, Selvaraj A, Davis A, Bloudoff K, Douglas J, Kiss B, Roberts M, Fazli L, Black PC, Fekkes P, Smith PG, Warmuth M, Yu L, Hao MH, Larsen N, Daugaard M, Zhu P.

Nat Commun. 2017 Jul 24;8(1):103. doi: 10.1038/s41467-017-00147-w.

4.

Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex.

Teng T, Tsai JH, Puyang X, Seiler M, Peng S, Prajapati S, Aird D, Buonamici S, Caleb B, Chan B, Corson L, Feala J, Fekkes P, Gerard B, Karr C, Korpal M, Liu X, T Lowe J, Mizui Y, Palacino J, Park E, Smith PG, Subramanian V, Wu ZJ, Zou J, Yu L, Chicas A, Warmuth M, Larsen N, Zhu P.

Nat Commun. 2017 May 25;8:15522. doi: 10.1038/ncomms15522.

5.

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms.

Korpal M, Feala J, Puyang X, Zou J, Ramos AH, Wu J, Baumeister T, Yu L, Warmuth M, Zhu P.

J Vis Exp. 2015 Dec 9;(106):e52879. doi: 10.3791/52879.

6.

TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.

Mounir Z, Lin F, Lin VG, Korn JM, Yu Y, Valdez R, Aina OH, Buchwalter G, Jaffe AB, Korpal M, Zhu P, Brown M, Cardiff RD, Rocnik JL, Yang Y, Pagliarini R.

Oncogene. 2015 Jul;34(29):3815-25. doi: 10.1038/onc.2014.308. Epub 2014 Sep 29.

PMID:
25263440
7.

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, Yuan J, Kovats SG, Kim S, Cooke VG, Monahan JE, Stegmeier F, Roberts TM, Sellers WR, Zhou W, Zhu P.

Cancer Discov. 2013 Sep;3(9):1030-43. doi: 10.1158/2159-8290.CD-13-0142. Epub 2013 Jul 10.

8.

Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT).

Grassian AR, Lin F, Barrett R, Liu Y, Jiang W, Korpal M, Astley H, Gitterman D, Henley T, Howes R, Levell J, Korn JM, Pagliarini R.

J Biol Chem. 2012 Dec 7;287(50):42180-94. doi: 10.1074/jbc.M112.417832. Epub 2012 Oct 4.

9.

Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization.

Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, Wei Y, Hu G, Garcia BA, Ragoussis J, Amadori D, Harris AL, Kang Y.

Nat Med. 2011 Aug 7;17(9):1101-8. doi: 10.1038/nm.2401.

10.

MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells.

Matsushima K, Isomoto H, Yamaguchi N, Inoue N, Machida H, Nakayama T, Hayashi T, Kunizaki M, Hidaka S, Nagayasu T, Nakashima M, Ujifuku K, Mitsutake N, Ohtsuru A, Yamashita S, Korpal M, Kang Y, Gregory PA, Goodall GJ, Kohno S, Nakao K.

J Transl Med. 2011 Mar 22;9:30. doi: 10.1186/1479-5876-9-30.

11.

Targeting the transforming growth factor-beta signalling pathway in metastatic cancer.

Korpal M, Kang Y.

Eur J Cancer. 2010 May;46(7):1232-40. doi: 10.1016/j.ejca.2010.02.040. Epub 2010 Mar 20. Review.

PMID:
20307969
12.

Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis.

Korpal M, Yan J, Lu X, Xu S, Lerit DA, Kang Y.

Nat Med. 2009 Aug;15(8):960-6. doi: 10.1038/nm.1943. Epub 2009 Jul 13.

PMID:
19597504
13.
14.

The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2.

Korpal M, Lee ES, Hu G, Kang Y.

J Biol Chem. 2008 May 30;283(22):14910-4. doi: 10.1074/jbc.C800074200. Epub 2008 Apr 14.

15.

RanBP10 is a cytoplasmic guanine nucleotide exchange factor that modulates noncentrosomal microtubules.

Schulze H, Dose M, Korpal M, Meyer I, Italiano JE Jr, Shivdasani RA.

J Biol Chem. 2008 May 16;283(20):14109-19. doi: 10.1074/jbc.M709397200. Epub 2008 Mar 17.

16.

Characterization of the megakaryocyte demarcation membrane system and its role in thrombopoiesis.

Schulze H, Korpal M, Hurov J, Kim SW, Zhang J, Cantley LC, Graf T, Shivdasani RA.

Blood. 2006 May 15;107(10):3868-75. Epub 2006 Jan 24.

17.
18.

[Human milk and its value].

Korpal M.

Pediatr Pol. 1982 Jan;57(1):83-7. Polish. No abstract available.

PMID:
7099781

Supplemental Content

Loading ...
Support Center